Losartan Reduces Trinitrobenzene Sulphonic Acid-Induced Colorectal Fibrosis in Rats

Intestinal fibrosis – a chronic and progressive process mediated by several factors – occurs in several fibrostenosing enteropathies, but most frequently in patients with Crohn’s disease (CD). Despite the advances made in the understanding of CD and its management over the past 20 years, surgical in...

Full description

Saved in:
Bibliographic Details
Main Authors: Dov Wengrower, Giuliana Zanninelli, Giovanni Latella, Stefano Necozione, Issa Metanes, Eran Israeli, Joseph Lysy, Mark Pines, Orit Papo, Eran Goldin
Format: Article
Language:English
Published: Wiley 2012-01-01
Series:Canadian Journal of Gastroenterology
Online Access:http://dx.doi.org/10.1155/2012/628268
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849693013128773632
author Dov Wengrower
Giuliana Zanninelli
Giovanni Latella
Stefano Necozione
Issa Metanes
Eran Israeli
Joseph Lysy
Mark Pines
Orit Papo
Eran Goldin
author_facet Dov Wengrower
Giuliana Zanninelli
Giovanni Latella
Stefano Necozione
Issa Metanes
Eran Israeli
Joseph Lysy
Mark Pines
Orit Papo
Eran Goldin
author_sort Dov Wengrower
collection DOAJ
description Intestinal fibrosis – a chronic and progressive process mediated by several factors – occurs in several fibrostenosing enteropathies, but most frequently in patients with Crohn’s disease (CD). Despite the advances made in the understanding of CD and its management over the past 20 years, surgical intervention remains the only treatment strategy for patients with fibrostenosing CD. The results of several studies, however, have suggested that fibrosis may be a reversible and/or preventable phenomenon. Following an overview summarizing the contemporary knowledge regarding the cellular, cytokine and growth factor interactions that contribute to inflammation and the progression of fibrosis, this article describes an experimental animal model of colitis resembling human CD, which the authors used to investigate whether losartan, an angiotensin II receptor antagonist, could be used as a prophylactic agent to reduce the risk of intestinal fibrosis and strictures in patients with CD.
format Article
id doaj-art-95c36824fb614ae79da433768095b4a2
institution DOAJ
issn 0835-7900
language English
publishDate 2012-01-01
publisher Wiley
record_format Article
series Canadian Journal of Gastroenterology
spelling doaj-art-95c36824fb614ae79da433768095b4a22025-08-20T03:20:33ZengWileyCanadian Journal of Gastroenterology0835-79002012-01-01261333910.1155/2012/628268Losartan Reduces Trinitrobenzene Sulphonic Acid-Induced Colorectal Fibrosis in RatsDov Wengrower0Giuliana Zanninelli1Giovanni Latella2Stefano Necozione3Issa Metanes4Eran Israeli5Joseph Lysy6Mark Pines7Orit Papo8Eran Goldin9Institute of Gastroenterology, Hadassah University Hospital, Jerusalem, IsraelGastroenterology Unit, University of L’Aquila, L’Aquila, ItalyGastroenterology Unit, University of L’Aquila, L’Aquila, ItalyClinical Epidemiology Unit, Department of Internal Medicine and Public Health, University of L’Aquila, L’Aquila, ItalyInstitute of Gastroenterology, Hadassah University Hospital, Jerusalem, IsraelInstitute of Gastroenterology, Hadassah University Hospital, Jerusalem, IsraelInstitute of Gastroenterology, Hadassah University Hospital, Jerusalem, IsraelInstitute of Animal Science, The Volcani Center, Bet Dagan, IsraelDepartment of Pathology, Hadassah University Hospital, Jerusalem, IsraelInstitute of Gastroenterology, Hadassah University Hospital, Jerusalem, IsraelIntestinal fibrosis – a chronic and progressive process mediated by several factors – occurs in several fibrostenosing enteropathies, but most frequently in patients with Crohn’s disease (CD). Despite the advances made in the understanding of CD and its management over the past 20 years, surgical intervention remains the only treatment strategy for patients with fibrostenosing CD. The results of several studies, however, have suggested that fibrosis may be a reversible and/or preventable phenomenon. Following an overview summarizing the contemporary knowledge regarding the cellular, cytokine and growth factor interactions that contribute to inflammation and the progression of fibrosis, this article describes an experimental animal model of colitis resembling human CD, which the authors used to investigate whether losartan, an angiotensin II receptor antagonist, could be used as a prophylactic agent to reduce the risk of intestinal fibrosis and strictures in patients with CD.http://dx.doi.org/10.1155/2012/628268
spellingShingle Dov Wengrower
Giuliana Zanninelli
Giovanni Latella
Stefano Necozione
Issa Metanes
Eran Israeli
Joseph Lysy
Mark Pines
Orit Papo
Eran Goldin
Losartan Reduces Trinitrobenzene Sulphonic Acid-Induced Colorectal Fibrosis in Rats
Canadian Journal of Gastroenterology
title Losartan Reduces Trinitrobenzene Sulphonic Acid-Induced Colorectal Fibrosis in Rats
title_full Losartan Reduces Trinitrobenzene Sulphonic Acid-Induced Colorectal Fibrosis in Rats
title_fullStr Losartan Reduces Trinitrobenzene Sulphonic Acid-Induced Colorectal Fibrosis in Rats
title_full_unstemmed Losartan Reduces Trinitrobenzene Sulphonic Acid-Induced Colorectal Fibrosis in Rats
title_short Losartan Reduces Trinitrobenzene Sulphonic Acid-Induced Colorectal Fibrosis in Rats
title_sort losartan reduces trinitrobenzene sulphonic acid induced colorectal fibrosis in rats
url http://dx.doi.org/10.1155/2012/628268
work_keys_str_mv AT dovwengrower losartanreducestrinitrobenzenesulphonicacidinducedcolorectalfibrosisinrats
AT giulianazanninelli losartanreducestrinitrobenzenesulphonicacidinducedcolorectalfibrosisinrats
AT giovannilatella losartanreducestrinitrobenzenesulphonicacidinducedcolorectalfibrosisinrats
AT stefanonecozione losartanreducestrinitrobenzenesulphonicacidinducedcolorectalfibrosisinrats
AT issametanes losartanreducestrinitrobenzenesulphonicacidinducedcolorectalfibrosisinrats
AT eranisraeli losartanreducestrinitrobenzenesulphonicacidinducedcolorectalfibrosisinrats
AT josephlysy losartanreducestrinitrobenzenesulphonicacidinducedcolorectalfibrosisinrats
AT markpines losartanreducestrinitrobenzenesulphonicacidinducedcolorectalfibrosisinrats
AT oritpapo losartanreducestrinitrobenzenesulphonicacidinducedcolorectalfibrosisinrats
AT erangoldin losartanreducestrinitrobenzenesulphonicacidinducedcolorectalfibrosisinrats